HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Cipla inks pact with ImmunoACT to commercialize talicabtagene autoleucel in Africa
Jan-21-2026

Cipla through its subsidiary, Medpro Pharmaceutica, has entered into an exclusive license and supply agreement with Immunoadoptive Cell Therapy (ImmunoACT). Under this partnership, the company will commercialize talicabtagene autoleucel, India’s first indigenously developed CAR-T cell therapy, in the Republic of South Africa, Algeria, and Morocco. As part of this collaboration, ImmunoACT will manufacture the product and the company will commercialize in the licensed African territories, thereby expanding access of this revolutionary new treatment to markets currently with unmet needs. 

Talicabtagene autoleucel (the product) is an autologous (of a patient’s own blood sample) anti-CD19 CAR-T indicated for the treatment of patients with relapsed or refractory B-cell Non-Hodgkin’s Lymphoma (B-NHL) and B-cell Acute Lymphoblastic Leukemia (B-ALL) who have failed standard lines of therapy. Administered to over 500 patients in India, the therapy has demonstrated high efficacy, durable responses, and a well-tolerated safety profile, leading to reduced ancillary healthcare costs.

Cipla is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).

  RELATED NEWS >>